Stock Exchange
Game-Changing HIV Drug Trial Results: Doravirine/Islatravir Shows Promising Efficacy
The Conference on Retroviruses and Opportunistic Infections 2025 brought a plethora of promising revelations in the field of HIV treatment. Held in the vibrant heart of San Francisco, this year’s late-breaking antiviral session unveiled groundbreaking research results that are set to redefine approaches to managing HIV in the future.